# Aflibercept 2mg Treat-and-Extend Protocol
# Based on best available knowledge June 2025
# Extraction date: 2025-06-08

# Required metadata
name: "Aflibercept 2mg Treat-and-Extend"
version: "1.0.0"
created_date: "2025-06-08"
author: "Clinical Economics Integration Team"
description: "Aflibercept 2mg treat-and-extend protocol based on current best practice"

# Core protocol parameters
protocol_type: "treat_and_extend"
min_interval_days: 49        # 7 weeks
max_interval_days: 140       # 20 weeks
extension_days: 14           # 2 weeks
shortening_days: 14          # 2 weeks (symmetric with extension)

# Required disease transitions - Based on VIEW 1/2 and combined literature data
# Note: Using values from VIEW studies and ALTAIR/VIEW/Mylight combined analysis
disease_transitions:
  NAIVE:
    NAIVE: 0.00
    STABLE: 0.67      # VIEW 1/2: 63-72% dry retina at week 52
    ACTIVE: 0.23      # VIEW 1/2: 20-25% controlled but not resolved
    HIGHLY_ACTIVE: 0.10
    
  STABLE:
    NAIVE: 0.00
    STABLE: 0.80      # From project data (79-83% range)
    ACTIVE: 0.15      # From project data (12-20% range)
    HIGHLY_ACTIVE: 0.05
    
  ACTIVE:
    NAIVE: 0.00
    STABLE: 0.30      # From project data (25-32% range)
    ACTIVE: 0.60      # From project data (57-65% range)
    HIGHLY_ACTIVE: 0.10
    
  HIGHLY_ACTIVE:
    NAIVE: 0.00
    STABLE: 0.15      # Conservative estimate
    ACTIVE: 0.35      # Conservative estimate
    HIGHLY_ACTIVE: 0.50

# Required vision change model - Based on VIEW 1/2 trials and project parameters
# Note: Using actual aflibercept 2mg data from VIEW studies
vision_change_model:
  naive_treated:
    mean: 8.4          # From VIEW 1/2 combined (52 weeks)
    std: 14.7          # From VIEW 1/2 combined
    
  naive_untreated:
    mean: -2.5         # From project data (natural history)
    std: 2.0
    
  stable_treated:
    mean: 1.0          # From project data (0.1-1.5 range)
    std: 1.5
    
  stable_untreated:
    mean: -0.75        # From project data
    std: 1.0
    
  active_treated:
    mean: 0.3          # From project data (-0.2 to +0.8 range)
    std: 2.0
    
  active_untreated:
    mean: -2.0         # From project data
    std: 2.5
    
  highly_active_treated:
    mean: -0.3         # From project data (-0.8 to +0.3 range)
    std: 3.0
    
  highly_active_untreated:
    mean: -4.0         # From project data
    std: 3.5

# Treatment effect on transitions - Based on project standards
treatment_effect_on_transitions:
  NAIVE:
    multipliers:
      NAIVE: 0.0
      STABLE: 1.5        # Treatment promotes stability
      ACTIVE: 0.7        # Reduces progression to active
      HIGHLY_ACTIVE: 0.5 # Significantly reduces progression to highly active
      
  STABLE:
    multipliers:
      NAIVE: 0.0
      STABLE: 1.2        # Helps maintain stability
      ACTIVE: 0.75       # Reduces deterioration
      HIGHLY_ACTIVE: 0.6
      
  ACTIVE:
    multipliers:
      NAIVE: 0.0
      STABLE: 1.4        # Promotes return to stable
      ACTIVE: 0.9
      HIGHLY_ACTIVE: 0.7
      
  HIGHLY_ACTIVE:
    multipliers:
      NAIVE: 0.0
      STABLE: 1.5        # Strong treatment effect for severe disease
      ACTIVE: 1.2
      HIGHLY_ACTIVE: 0.8

# Baseline vision parameters
baseline_vision:
  mean: 55             # Typical trial entry criteria
  std: 15
  min: 25              # Minimum for treatment (guidance threshold)
  max: 85

# Discontinuation rules - Based on current best practice
discontinuation_rules:
  # Stable disease at extended interval
  stable_extended_interval:
    criteria:
      consecutive_stable_visits: 3
      minimum_interval_weeks: 7     # Cannot extend beyond this
    probability: 0.10
    reason: "stable_disease"
    
  # Poor response - primary criterion
  poor_response_25_letters:
    criteria:
      va_less_than: 25              # < 25 letters absolute
      consecutive_visits: 2         # On 2 consecutive visits
      attributable_to_amd: true
    probability: 0.95
    reason: "poor_response"
    
  # Critical vision loss
  critical_vision_15_letters:
    criteria:
      va_less_than: 15              # < 15 letters absolute
      consecutive_visits: 2
    probability: 0.99
    reason: "severe_vision_loss"
    
  # Unable to extend intervals
  frequent_injections:
    criteria:
      max_achieved_interval_weeks: 7  # Cannot extend beyond 7 weeks
      attempts: 2                     # After 2 failed extension attempts
      months_on_treatment: 12
    probability: 0.50                # May switch or stop
    reason: "treatment_burden"
    
  # Non-compliance
  non_compliance:
    criteria:
      missed_consecutive_visits: 2
      months_since_last_visit: 4
    probability: 0.95
    reason: "lost_to_follow_up"
    
  # Adverse events
  adverse_event:
    criteria:
      severe_adverse_event: true
    probability: 0.90
    reason: "adverse_event"

# Protocol-specific parameters
treat_and_extend_parameters:
  # Loading phase - Based on standard practice
  loading_phase:
    number_of_doses: 3
    interval_days: 28               # Monthly
    
  # Extension/reduction rules
  extension_rules:
    stable_criteria:
      no_disease_activity: true     # OCT dry
      va_stable_or_improved: true
    extend_by_days: 14              # 2 weeks
    max_extension_days: 28          # Up to 4 weeks per guidance
    
  reduction_rules:
    active_criteria:
      disease_activity: true        # OCT shows fluid
      va_deterioration: true        # Loss of letters
    reduce_by_days: 14              # 2 weeks
    min_interval_days: 28           # Not less than monthly
    
  # Treatment switching criteria
  switch_criteria:
    suboptimal_after_loading: true
    frequent_injections_threshold_weeks: 8
    failed_extension_attempts: 2
    
  # Maximum lines of therapy
  max_lines_of_therapy: 3

# Clinical evidence basis
clinical_evidence:
  source: "Based on VIEW 1/2 pivotal trials and current clinical practice"
  key_data:
    - "VIEW 1/2: Mean +8.4 letters at 52 weeks (SD 14.7)"
    - "VIEW 1/2: 67.7% achieved dry retina at week 52"
    - "VIEW 1/2: 95.3% maintained vision, 31% gained â‰¥15 letters"
    - "Combined analysis (ALTAIR/VIEW/Mylight): Consistent outcomes"
  key_principles:
    - "First choice: Aflibercept 2mg (switch to biosimilar when available)"
    - "Maximum 3 lines of therapy per eye"
    - "Switch if unable to extend beyond 7 weeks after 2 attempts"
  limitations:
    - "Loading phase confirmed as 3 monthly doses from VIEW trials"
    - "Some transition probabilities adapted from treat-and-extend data"
    - "VIEW used fixed dosing; T&E parameters inferred"